Next Capital Management LLC Buys Shares of 3,256 Illumina, Inc. $ILMN

Next Capital Management LLC bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 3,256 shares of the life sciences company’s stock, valued at approximately $573,000.

Other hedge funds have also made changes to their positions in the company. Empowered Funds LLC increased its stake in shares of Illumina by 113.7% during the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after buying an additional 4,940 shares during the period. Sivia Capital Partners LLC purchased a new stake in Illumina in the second quarter worth about $621,000. CW Advisors LLC purchased a new stake in Illumina in the second quarter worth about $275,000. Marshall Wace LLP grew its holdings in Illumina by 49.0% during the 2nd quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock worth $5,691,000 after acquiring an additional 19,618 shares in the last quarter. Finally, Cresset Asset Management LLC grew its holdings in Illumina by 30.9% during the 2nd quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock worth $706,000 after acquiring an additional 1,748 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Price Performance

Shares of ILMN stock opened at $190.89 on Friday. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $207.00. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The firm has a market capitalization of $28.82 billion, a price-to-earnings ratio of 35.61, a PEG ratio of 2.71 and a beta of 1.45. The stock’s 50-day simple moving average is $183.78 and its 200-day simple moving average is $150.56.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Insider Transactions at Illumina

In other news, insider Scott M. Davies sold 615 shares of the stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $200.00, for a total value of $123,000.00. Following the transaction, the insider directly owned 20,338 shares of the company’s stock, valued at approximately $4,067,600. This represents a 2.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the transaction, the senior vice president owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. The trade was a 3.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,415,351 shares of company stock worth $255,966,311 in the last 90 days. 2.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ILMN. Piper Sandler reissued an “overweight” rating and set a $225.00 target price (up from $200.00) on shares of Illumina in a research report on Monday, August 3rd. Deutsche Bank Aktiengesellschaft cut shares of Illumina to a “hold” rating in a research report on Wednesday, August 5th. Zacks Research upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 3rd. Evercore reissued an “outperform” rating on shares of Illumina in a report on Monday, July 6th. Finally, Wall Street Zen raised shares of Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $188.40.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.